Development of a DNA-MVA/HIVA vaccine for Kenya.

Development of a DNA-MVA/HIVA vaccine for Kenya.

Without going into the details of the devastation that human immunodeficiency virus (HIV) infection causes especially in the developing world, the best hope for changing the course of this epidemic is development of a safe, effective, accessible prophylactic HIV vaccine. While the inaccessibility of...

Full description

Bibliographic Details
Main Authors:	Hanke, T, Mcmichael, A, Mwau, M, Wee, E, Ceberej, I, Patel, S, Sutton, J, Tomlinson, M, Samuel, R
Format:	Journal article
Language:	English
Published:	2002

Similar Items

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
by: Wee, E, et al.
Published: (2002)

Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.
by: Saubi, N, et al.
Published: (2011)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
by: Saubi, N, et al.
Published: (2011)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
by: Im, E, et al.
Published: (2006)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
by: Hanke, T, et al.
Published: (2002)

Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS.
by: Hanke, T, et al.
Published: (1999)

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
by: Guimarães-Walker, A, et al.
Published: (2008)

Corrigendum to " Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677]
by: Guimarães-Walker, A, et al.
Published: (2011)

A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants
by: Afolabi, M, et al.
Published: (2013)

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
by: Nkolola, J, et al.
Published: (2004)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
by: Mwau, M, et al.
Published: (2004)

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008)
by: Guimaraes-Walker, A, et al.
Published: (2011)

Design and tests of an HIV vaccine.
by: McMichael, A, et al.
Published: (2002)

HIV T cell vaccines, the importance of clades.
by: McMichael, A, et al.
Published: (2002)

Corrigendum to "Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers" [Vaccine 26 (2008) 6671-6677] (DOI:10.1016/j.vaccine.2008.09.016)
by: Guimarães-Walker, A, et al.
Published: (2011)

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
by: Mwau, M, et al.
Published: (2002)

MVA as a vector for vaccines against HIV-1.
by: Im, E, et al.
Published: (2004)

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
by: Afolabi, M, et al.
Published: (2011)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
by: Njuguna, I, et al.
Published: (2014)

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
by: Saubi, N, et al.
Published: (2012)

PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.
by: Njuguna, I, et al.
Published: (2014)

A review of vaccines for HIV prevention.
by: Mwau, M, et al.
Published: (2003)

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.
by: Hanke, T, et al.
Published: (1998)

Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG
by: Saubi, N, et al.
Published: (2012)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
by: Estcourt, M, et al.
Published: (2005)

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.
by: Hanke, T, et al.
Published: (2000)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
by: Hanke, T, et al.
Published: (2005)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)

DNA vaccines against human immunodeficiency virus type 1.
by: Estcourt, M, et al.
Published: (2004)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
by: Slyker, J, et al.
Published: (2005)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
by: Mahant, A, et al.
Published: (2017)

On DNA vaccines and prolonged expression of immunogens.
by: Hanke, T
Published: (2006)

Generation of multivalent recombinant MVA vaccines for malaria
by: Orubu, T
Published: (2012)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
by: Schmidt, C, et al.
Published: (2008)